Evidence map›Paper›PMID 22703118›Full record

ArticleBMC cancer2012

Microtubule S-glutathionylation as a potential approach for antimitotic agents.

Wei Chen, Teresa Seefeldt, Alan Young, Xiaoying Zhang, Yong Zhao, John Ruffolo, Radhey S Kaushik, Xiangming Guan

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Metabolic Shades of S-D-Lactoylglutathione.Antioxidants (Basel, Switzerland) · 2022
    Review
  4. Redox-Related Proteins in Melanoma Progression.Antioxidants (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Dysregulation of the glutaredoxin/American journal of physiology. Cell physiology · 2020
    Article
  8. Review
  9. Review
  10. GlutathioneDrug design, development and therapy · 2018
    Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Wei ChenZhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China.
Teresa Seefeldt
Alan Young
Xiaoying Zhang
Yong Zhao
John Ruffolo
Radhey S Kaushik
Xiangming Guan
South Dakota State University · USMichigan State University · USZhejiang Cancer Hospital · CN

Funding

Inhibition of glutathione reductase and ovarian cancer drug resistance reversalR15CA120062 · NCI · SOUTH DAKOTA STATE UNIVERSITY · PI GUAN, XIANGMING · 2006 to 2006
$213k
Glutathione reductase and tumor sensitivity to radiationR15CA098810 · NCI · SOUTH DAKOTA STATE UNIVERSITY · PI GUAN, XIANGMING · 2003 to 2003
$141k
NCI NIH HHS CA098810-01NCI NIH HHS CA120062-01
6 · The paper itself

Abstract

backgroundMicrotubules have been one of the most effective targets for the development of anticancer agents. Cancer cells treated by these agents are characterized by cell arrest at G2/M phase. Microtubule-targeting drugs are, therefore, referred to as antimitotic agents. However, the clinical application of the current antimitotic drugs is hampered by emerging drug resistance which is the major cause of cancer treatment failure. The clinical success of antimitotic drugs and emerging drug resistance has prompted a search for new antimitotic agents, especially those with novel mechanisms of action. The aim of this study was to determine whether microtubules can be S-glutathionylated in cancer cells and whether the glutathionylation will lead to microtubule dysfunction and cell growth inhibition. The study will determine whether microtubule S-glutathionylation can be a novel approach for antimitotic agents.

methods2-Acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylcarbonylamino)phenyl carbamoylsulfanyl]propionic acid (2-AAPA) was used as a tool to induce microtubule S-glutathionylation. UACC-62 cells, a human melanoma cell line, were used as a cancer cell model. A pull-down assay with glutathione S-transferase (GST)-agarose beads followed by Western blot analysis was employed to confirm microtubule S-glutathionylation. Immunofluorescence microscopy using a mouse monoclonal anti-α-tubulin-FITC was used to study the effect of the S-glutathionylation on microtubule function; mainly polymerization and depolymerization. Flow cytometry was employed to examine the effect of the S-glutathionylation on cell cycle distribution and apoptosis. Cell morphological change was followed through the use of a Zeiss AXIO Observer A1 microscope. Cancer cell growth inhibition by 2-AAPA was investigated with ten human cancer cell lines.

resultsOur investigation demonstrated that cell morphology was changed and microtubules were S-glutathionylated in the presence of 2-AAPA in UACC-62 cells. Accordingly, microtubules were found depolymerized and cells were arrested at G2/M phase. The affected cells were found to undergo apoptosis. Cancer growth inhibition experiments demonstrated that the concentrations of 2-AAPA required to produce the effects on microtubules were compatible to the concentrations producing cancer cell growth inhibition.

conclusionsThe data from this investigation confirms that microtubule S-glutathionylation leads to microtubule dysfunction and cell growth inhibition and can be a novel approach for developing antimitotic agents.

Indexed as

Antimitotic AgentsApoptosisBlotting, WesternCell Line, TumorCell ProliferationChromatography, High Pressure LiquidFlow CytometryGlutathioneHumansMicroscopy, FluorescenceMicrotubulesPropionates2-amino-3-(4-aminophenyl)propionic acidAntimitotic AgentsGlutathionePropionates

Identifiers

PMID22703118
PMCPMC3534152
OpenAlexW2020735894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.